Eosinophilic otitis media and comorbid asthma

Curr Opin Allergy Clin Immunol. 2020 Feb;20(1):9-13. doi: 10.1097/ACI.0000000000000589.

Abstract

Purpose of review: Eosinophilic otitis media (EOM) is an intractable otitis media characterized by numerous eosinophils infiltrating the middle ear cavity, which is part of the upper airway. EOM shows a high rate of comorbidity with asthma. They are considered to have a 'one airway, one disease' relationship. Here, we summarize our current knowledge regarding the characteristics of EOM, EOM's relationship with asthma and the efficacy of optimal treatments for EOM.

Recent findings: The greater the severity of asthma, the more pronounced the development of EOM. Asthma control is usually inadequate in asthmatics who develop EOM, and appropriate strengthening of asthma inhalation therapy leads to improvement in the EOM. EOM severity can be divided into mild, moderate, and severe. Intratympanic infusion therapy using a topical steroid such as triamcinolone acetone is effective for mild EOM, whereas moderate EOM requires a systemic steroid in addition to triamcinolone acetone, and severe EOM forms granulation tissue that requires surgical removal. Recently, the effectiveness of molecularly targeted drugs is being reported, but more data need to be accumulated.

Summary: EOM and asthma are closely related. Optimal asthma treatment is important for treating EOM. Treatments commensurate with the severity of EOM are being developed.

Publication types

  • Review

MeSH terms

  • Asthma / drug therapy
  • Asthma / epidemiology
  • Asthma / immunology*
  • Comorbidity
  • Eosinophilia
  • Eosinophils / immunology*
  • Eustachian Tube / immunology*
  • Humans
  • Injection, Intratympanic
  • Molecular Targeted Therapy
  • Otitis Media / drug therapy
  • Otitis Media / epidemiology
  • Otitis Media / immunology*
  • Triamcinolone Acetonide / therapeutic use

Substances

  • Triamcinolone Acetonide